Metabolic Tumor Volume Metrics in Lymphoma.
暂无分享,去创建一个
[1] Xiaoping Zhou,et al. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma , 2016, Oncotarget.
[2] Piernicola Pedicini,et al. F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma , 2014, European journal of haematology.
[3] Deborah A. Bowen,et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma , 2014, Leukemia & lymphoma.
[4] E. Malek,et al. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods , 2015, Blood Cancer Journal.
[5] J. Briones,et al. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[6] A. Zelenetz,et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Adriaan A. Lammertsma,et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[9] R. Foà,et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease , 2015, Leukemia.
[10] P. Christian,et al. Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom , 2015, The Journal of Nuclear Medicine.
[11] Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. , 2015, Blood.
[12] D. Hasenclever,et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[13] U. Jaeger,et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.
[14] A. Tsimberidou,et al. Richter syndrome , 2005, Cancer.
[15] Ursula Nestle,et al. Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.
[16] D. Groheux,et al. Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer , 2013, Clinical nuclear medicine.
[17] I. Steffen,et al. FDG-PET Response Prediction in Pediatric Hodgkin’s Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value , 2015, Cancers.
[18] D. Mariano-Goulart,et al. Association between textural and morphological tumor indices on baseline PET‐CT and early metabolic response on interim PET‐CT in bulky malignant lymphomas , 2017, Medical physics.
[19] Claude Nahmias,et al. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.
[20] Sasa Mutic,et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[21] L. Ceriani,et al. 18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma , 2012, Clinical nuclear medicine.
[22] Di Yan,et al. Defining a radiotherapy target with positron emission tomography. , 2002, International journal of radiation oncology, biology, physics.
[23] E. Hindié,et al. Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma , 2015, Clinical nuclear medicine.
[24] Xiaodong Wu,et al. Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. , 2012, IEEE transactions on medical imaging.
[25] G. Salles,et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s Syndrome , 2016, Leukemia & lymphoma.
[26] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[27] E. Palmer,et al. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. , 2013, American journal of nuclear medicine and molecular imaging.
[28] Jan-Jakob Sonke,et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] F. Brunotte,et al. Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients , 2014, The Journal of Nuclear Medicine.
[30] Robert Jeraj,et al. Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.
[31] Yanhui Xie,et al. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma , 2015, Hematology.
[32] Y. Erdi,et al. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .
[33] Stuart A. Taylor,et al. Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma? , 2011, Cancer biomarkers : section A of Disease markers.
[34] Joel S. Karp,et al. Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.
[35] M. Czuczman,et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[37] H. Jacobsson,et al. The relation between the blood glucose level and the FDG uptake of tissues at normal PET examinations , 2013, EJNMMI Research.
[38] Joshua J Gagne,et al. Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.
[39] R. Boellaard,et al. 18F-FDG or 3′-Deoxy-3′-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma , 2015, The Journal of Nuclear Medicine.
[40] Ronald Boellaard,et al. Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[41] Habib Zaidi,et al. A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET. , 2010, Medical physics.
[42] R. Boellaard,et al. Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis , 2012, The Journal of Nuclear Medicine.
[43] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Yan Liu,et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants , 2014, Medical Oncology.
[45] Ho-Jin Shin,et al. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.
[46] M. Matoba,et al. Diagnostic Performance of Diffusion-Weighted Imaging for Multiple Hilar and Mediastinal Lymph Nodes with FDG Accumulation. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[47] P. Christian,et al. Use of a precision fillable clinical simulator phantom for PET/CT scanner validation in multi-center clinical trials: The SNM Clinical Trials Network (CTN) Program , 2012 .
[48] Pierre Vera,et al. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma , 2015, Clinical Cancer Research.
[49] G Loi,et al. Threshold segmentation for PET target volume delineation in radiation treatment planning: the role of target-to-background ratio and target size. , 2008, Medical physics.
[50] G. Salles,et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] C. Copie-Bergman,et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] C. Wassberg,et al. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. , 2015, Clinical radiology.
[53] H. Tilly,et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[54] M. Hatt,et al. Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.
[55] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Boellaard. Methodological aspects of multicenter studies with quantitative PET. , 2011, Methods in molecular biology.
[57] Rakesh Kumar,et al. Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation , 2011, Annals of Nuclear Medicine.
[58] I. Buvat,et al. Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET , 2010, Journal of Nuclear Medicine.
[59] R. Boellaard,et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies , 2009, Journal of Nuclear Medicine.
[60] K. Ishii,et al. Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma , 2015, EJNMMI Research.
[61] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Lambin,et al. Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability , 2013, Acta oncologica.
[63] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[64] Stephane Chauvie,et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.
[65] E. Noordijk,et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[66] J. Yahalom,et al. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) , 2005, European journal of haematology. Supplementum.
[67] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[69] P. Moreau,et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma , 2008, Haematologica.
[70] A. Ng,et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.
[71] T. Kwee,et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole‐body volumetric–metabolic FDG‐PET/CT metrics in diffuse large B‐cell lymphoma , 2015, European journal of haematology.
[72] L. Specht,et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.
[73] E. Laffon,et al. On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Martin A Lodge,et al. Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value , 2012, The Journal of Nuclear Medicine.
[75] Z. Estrov,et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. , 2014, Blood.
[76] Andrew Homb,et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.
[77] S. Barrington,et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[78] A. Rahmouni,et al. Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.
[79] Seong-Jang Kim,et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.
[80] H. Tilly,et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[81] I. Steffen,et al. SUV‐measurements and patient‐specific corrections in pediatric Hodgkin‐lymphoma: Is there a benefit for PPV in early response assessment by FDG‐PET? , 2012, Pediatric blood & cancer.
[82] P. Gobbi,et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma , 2004, Cancer.
[83] Paul Kinahan,et al. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[84] John L. Humm,et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[85] R. Wahl,et al. 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy , 2008, Journal of Nuclear Medicine.
[86] I. Steffen,et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] M. Goodman,et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. , 2011, International journal of radiation oncology, biology, physics.
[88] Mithat Gönen,et al. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. , 2011, International journal of radiation oncology, biology, physics.
[89] Jan-Jakob Sonke,et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer , 2013, BMC Cancer.
[90] Dimitris Visvikis,et al. Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.
[91] S. Ferrero,et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.
[92] R. Munden,et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[94] Charles F Hildebolt,et al. Diffusion‐weighted MRI for staging and evaluation of response in diffuse large B‐cell lymphoma: a pilot study , 2014, NMR in biomedicine.
[95] Assen S. Kirov,et al. Pathology-validated PET image data sets and their role in PET segmentation , 2014, Clinical and Translational Imaging.
[96] Vincent Grégoire,et al. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[97] Vicky Goh,et al. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[98] P. Gobbi,et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] R. Lhommel,et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma , 2014, Leukemia and Lymphoma.
[100] D. Mollura,et al. Predicting Future Morphological Changes of Lesions from Radiotracer Uptake in 18F-FDG-PET Images , 2013, PloS one.
[101] Alexandre Cochet,et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[102] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[103] R. Boellaard,et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[104] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.
[105] Dong Soo Lee,et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma , 2013, Cancer.
[106] H. Eich,et al. Involved-Node Radiotherapy in Early-Stage Hodgkin’s Lymphoma , 2008, Strahlentherapie und Onkologie.
[107] A. Bhattacharya,et al. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin’s lymphoma , 2012, Nuclear medicine communications.
[108] R. Advani,et al. Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease , 2012, Radiation oncology.
[109] Y. Oki,et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma , 2011, International journal of hematology.
[110] Y. Tamaki,et al. Quality assurance of radiotherapy in a clinical trial for lymphoma: individual case review. , 2007, Anticancer research.
[111] G. Baroni,et al. Radiotherapy of Hodgkin and Non-Hodgkin Lymphoma , 2016, Technology in cancer research & treatment.
[112] Anne Bol,et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[113] Habib Zaidi,et al. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[114] K. Murase,et al. Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five PET scanners , 2008, Annals of nuclear medicine.
[115] J. Choi,et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma , 2012, American journal of hematology.
[116] R. Fisher,et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[118] Andre Dekker,et al. Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.
[119] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[120] Fréderic Duprez,et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[121] J. Radford,et al. Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] Steve Y. Cho,et al. Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma. , 2015, Practical radiation oncology.
[123] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[124] Kyung Hoon Hwang,et al. Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease , 2014, Nuclear Medicine and Molecular Imaging.
[125] C. Mamot,et al. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] R. Advani,et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[127] C. Rübe,et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[128] L. Sehn,et al. Erratum: An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era (Blood (2014) 123:6 (837-842)) , 2014 .
[129] Carole Lartizien,et al. Computer-Aided Staging of Lymphoma Patients With FDG PET/CT Imaging Based on Textural Information , 2012, IEEE Journal of Biomedical and Health Informatics.
[130] H. Eich,et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.
[131] V. Grégoire,et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[132] A. Moreau,et al. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin’s disease , 2008, Haematologica.
[133] Seong-Jang Kim,et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma , 2013, Cancer science.
[134] M. Gönen,et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[135] M. Kersten,et al. Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. , 2014, American journal of nuclear medicine and molecular imaging.
[136] H. Holte,et al. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma , 2015, Acta radiologica.
[137] F. Jardin,et al. Does enhanced CT influence the biological GTV measurement on FDG-PET images? , 2013, Radiotherapy and Oncology.
[138] R. Boellaard,et al. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments , 2009, Leukemia & lymphoma.
[139] G. Salles,et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. , 2017, Blood.
[140] B. Coiffier,et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.